Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 18th Annual Congress on Pharmaceutics & Drug Delivery Systems Holiday Inn Amsterdam – Arena Towers. Amsterdam, Netherlands.

Day 1 :

Keynote Forum

Amots Dafni

Haifa University Israel

Keynote: Medicinal plants of the bible - past, present and future
Euro Pharmaceutics 2019 International Conference Keynote Speaker Amots Dafni  photo
Biography:

Dr. Dafni is a researcher at the "Laboratory of Ecology and Pollination, Institute of Evolution",In the Hebrew University of Jerusalem he obtained in 1967 his B.Sc. in Biology, in 1969 the Teacher's Certificate, in 1970 his M.Sc. in Botany, and from 1971 to 1975 he studied Doctorate, defending the thesis: "Comparative Biology of Prosopis farcta populations from different habitats in Israel.

 

Abstract:

Based on data on archaeobotany and ethnobotany of the Holy Land, survey of the use of Medicinal plants in the Holy Land throughout history as well as at the present time , and a Revision of the medicinal plant of Assyria we suggest a new list of the Medicinal Plants of the bible. While Duke and Duke (1983) enumerated not less than 176 plant species as “Biblical Medicinal Plants” and Jacob (1993) only 54, in our survey we suggest reducing that figure to 37. The overlap between Jacob’s list and ours is 19 species in total. Our contribution is 18 “new” suggested Biblical Medicinal Plants.

This discrepancy is due to three reasons:

1. Not less than 22 species in Jacob’s list are not recognized today (Amar, 2012) as valid Biblical plants names at all, or they are not related to specific species.

2. Several identifications from Campbell-Thompson (1949), the only Mesopotamian source used by Jacob, are no longer recognized by modern Assyriologists.

3. Several Mesopotamian plants were only recently identified in medical context.

In our list there are three groups:

1. Plants which are mentioned directly as medicinal plants in the Bible: Fig (Ficus carica), Nard (Nardostachys jatamansi), Hyssop (Majorana syriaca), Balm of Gilead (Commiphora gileadensis) and Mandrake (Mandragora officinarum= M. autumnalis).

2. Plants which are mentioned in the bible and are known as medicinal in post Biblical Jewish sources and / or Egypt and/or Mesopotamia (28spp.)

3. Plant which are not mentioned in the Bible but are present in the Holy Land and are known as medicinal in post Biblical Jewish sources and / or Egypt and/or Mesopotamia (12 spp.) According to our survey, all the 45 suggested BMP’s are still in medical use today in the Middle East and are subjected, at the 21 century, to an active research in attempts; to understand their chemical composition and/or Medical activity and/or Isolation of new compounds for new drug development. Shakya (2016) mentioned “Top 25 Bioactive Compounds of Medicinal plants”, his list includes also : Curcuma longa, Ricinus communis, Piper nigrum, Aloe vera, Nigella sativa, Artemisia absinthium and Allium sativa = 24% of our list of Biblical Medicinal Plants!!

As written in the Bible: “That which has been is what will be, that which is done is what will be done, And there is nothing new under the sun”.

 

 

Euro Pharmaceutics 2019 International Conference Keynote Speaker Radostina Alexandrova photo
Biography:

Radostina Alexandrova has completed her graduation with honors in Biochemistry and Microbiology from Sofia University “St. Kl. Ohridski” (SU) in 1991; MSc and PhD in Virology; Post-doctoral training in Slovakia, Hungary, Denmark, Iceland; Lecturer in SU and PhD School of Bulgarian Academy of Sciences (BAS). She is a Team-Leader in the Department of Pathology, IEMPAM-BAS. She has published more than 150 papers in reputed journals and conference proceedings.

 

Abstract:

A wide range of Schiff bases and especially their metal complexes have been reported to exhibit promising antitumor activity. In addition, there are data confirming the anticancer potential of various Ru(II) and Ru(III) complexes in model systems in vitro and in vivo. The aim of our study was to evaluate the cytotoxic activity of six newly synthesized ruthenium(III) complexes with Schiff bases resulted from the condensation reaction of salicylaldehyde with ethylenediamine (H2Salen), 1,3-diaminopropane (H2Salpn) and 1,2-phenylenediamine (H2Salphen), respectively; and from the condensation reaction of o-vanillin with ethylenediamine (H2Valen), 1,3-diaminopropane (H2Valpn) and, respectively 1,2-phenylenediamine (H2Valphen). Cell lines established from human breast cancer (MCF-7, MDA-MB-231) and cervical carcinoma (HeLa) as well as non-tumor human embryonic fibroblastoid cells (Lep-3) were used as model systems in our investigations. The effect of the compounds on cell viability and proliferation was examined by thiazolyl blue tetrazolium bromide (MTT) test, neutral red uptake cytotoxicity assay, crystal violet staining, double staining with acridine orange and propidium iodide, hematoxylin and eosin staining, AnnexinV/ICH - DAB and/or AnnexinV/FITC, colony-forming method. The compounds were applied at a concentration range of 5-100 µg/ml for 24-72 h (in short-term experiments, with monolayer cultures) and 25-30 days (in long-term experiments, with 3D cancer cell colonies). The results obtained revealed that the examined metal complexes reduced significantly viability and/or proliferation of the treated cells in a time - and concentration - dependent manner.

 

Euro Pharmaceutics 2019 International Conference Keynote Speaker Nuzhat Chalisa photo
Biography:

Dr. Chalisa is a Clinical Endocrinologist practicing in Chicago IL for past 20 years. Dr. Chalisa started her career in United states as a research assistant in Hepatology with Dr. David Vanthiel at Loyola university medical center in Chicago IL.  She completed her Internal medicine training at Loyola university Hospital in Chicago. She did fellowship in Endocrinology Diabetes and metabolism at the Rosalind Franklin university of health sciences. Dr. Chalisa’s primary interest has been in the area of Diabetes. Her experience crosses between research and clinical practice. Some of her initial research was on age related cognitive decline in diabetics and continuous glucose monitoring. She was then focused on clinical practice for few years. She has been interviewed and have published several articles on Diabetes in local newspapers and Journals and has been a speaker in several International diabetes conferences.

 

Abstract:

Diabetes is a growing global health concern that affects all age groups and genders. Analysts predict a worldwide prevalence of 552 million people with diabetes by 2030. Uncontrolled diabetes can lead to acute complications, including but not limited to, hypoglycemia, hyperglycemia, diabetic coma, diabetic ketoacidosis, and diabetic non-ketotic hyperosmolar coma.

Recurrent ongoing hyperglycemia can lead to chronic complications. These complications occur due to a mix of microangiopathy, macrovascular disease, and immune dysfunction. Microangiopathy can affect all vital organs, including they kidneys, heart, and brain, as well as eyes, nerves, lungs, and local gums and feet. Macrovascular problems can lead to cardiovascular disease, stroke, and peripheral vascular disease leading to gangrene and amputation. The damaging effects of hyperglycemia on the vasculature significantly contribute to diabetes complications and comorbidities. Between 30% and 50% of all diabetic patients have some organ damage, which can potentially progress to long-term complications. Hyperglycemia is toxic, whether it occurs early or later in life, and regardless of its etiology.

Comorbidities compound the chronic complications of diabetes. These include smoking, obesity, high blood pressure, and/or elevated cholesterol levels. Additionally, there are many other complications of diabetes which are not recognized and often remain unaddressed, such as diabetic dermopathy, osteoporosis, sleep apnea, musculoskeletal impairments, gastroparesis and dental problems, mental health issues, and vitamin deficiencies.

Type 2 diabetes has been disproportionately increasing in minority populations. Non-Caucasian populations such as Hispanics, African Americans, and Asians are much more likely to develop type 2 diabetes and less likely to have effective control. Certain ethnic populations have a higher risk of complications from diabetes than others.

In addition to the societal and humanistic effects, the management of diabetes and its’ complications has substantial economic impact. If diabetes is undetected or its complications are poorly managed, patients can experience a poor health-related quality of life with significant morbidity and mortality, so optimal prevention and treatment strategies are necessary.

Adequate and sustained control of blood sugar levels can prevent or delay the onset of diabetes-related complications. However, effective interventions, at both the individual and population levels, are desperately needed to slow the diabetes epidemic and reduce the burden of diabetes-related complications.